Plasma extracellular RNAs have recently garnered interest as biomarkers in heart failure (HF). Most studies in HF focus on single extracellular RNAs related to phenotypes and outcomes, and few describe their functional roles. We hypothesized that clusters of plasma microRNAs (miRNAs) associated with left ventricular (LV) remodeling in human HF would identify novel subsets of genes involved in HF in animal models.
D
espite an emerging recognition of diverse molecular mechanisms (apoptosis, fibrosis, and autophagy) involved in adverse left ventricular (LV) remodeling, current strategies to identify risk of LV remodeling based on clinical indices or circulating biomarkers are only modestly successful. Biomarkers stable in circulation and functionally implicated in LV remodeling are likely to be useful in this context. Accordingly, microRNAs (miRNAs)-small, 21-22-mer extracellular RNAs involved in modulation of target mRNA expression across a variety of tissues-have been increasingly implicated in processes relevant to heart failure (HF), including myocardial fibrosis and hypertrophy. [1] [2] [3] Dysregulation of noncoding RNA expression in the failing heart 4, 5 and in circulation during hemodynamic unloading or cardiac resynchronization has been reported. [6] [7] [8] [9] [10] Nevertheless, most of these studies either (1) separately identify different miRNAs associated with phenotypes or outcomes in humans or (2) study gain-and loss-of-function of single candidate miRNAs in animal systems. With the advent of next-generation sequencing and high-throughput precision medicine efforts, it is increasingly clear that networks of molecular mediators are relevant in complex traits. 11, 12 Moreover, distinct miRNAs can target similar mRNAs. 13 Given the promiscuity of different miRNAs to target genes involved in similar pathways, selection of clusters of miRNAs that (1) influence common pathways relevant to HF and (2) are based on human HF phenotypes may provide the strongest approach to pathway discovery.
In this study, we address this step by studying 64 patients with chronic HF and reduced ejection fraction with available blood samples who underwent serial echocardiography before and 10 months after guideline-directed medical therapy to identify clusters of miRNAs at baseline that identify individuals with favorable reverse LV remodeling phenotypes for 6 months. Using principal components analysis (PCA), we identified a cluster of miRNAs that provided discrimination of risk of LV remodeling. We subsequently subjected these target miRNAs to in silico network analysis to identify genes (several which were not previously widely implicated in HF) that were targeted by >1 miRNA for assessment in a murine model of hypertrophy and HF. Ultimately, the goal of this work was to establish a novel translational paradigm for pathway discovery in HF.
METHODS
The data, analytic methods, and study materials will be made available to other researchers for purposes of reproducing the results or replicating the procedure. All data and materials have been made publicly available at GEO and can be accessed as accession number GSE109051. 14 
Study Population
The PROTECT (Pro-BNP Outpatient Tailored Chronic HF Therapy) trial was a single-center, prospective, randomized controlled trial enrolling 151 patients with LV systolic dysfunction (LV ejection fraction <40%). The primary aim of the PROTECT study was to test the hypothesis that standard of care HF management targeted to maintain an N-terminal pro-B-type natriuretic peptide level ≤1000 pg/mL would be superior to standard of care management. 15 For this study, we focused on 64 study participants with (1) available plasma samples at baseline, prerandomization study visit and (2) 2-dimensional transthoracic echocardiographic measurements at baseline and an average of 10-month postrandomization of LV end-systolic volume index and LV ejection fraction. Standard clinical and demographic characteristics were measured via questionnaire and physical examination at study enrollment and have been previously described. 16 Venous blood was collected via peripheral venipuncture, centrifuged, and stored at −80°C for future analysis. Our local institutional review board approved all study procedures, and all subjects gave written informed consent before enrollment.
WHAT IS NEW?
• Plasma extracellular RNAs are stable circulating RNAs that have been implicated in heart failure (HF). However, their relationship to changes in cardiac structure (remodeling) relevant to HF remains unexplored. Here, we use a cohort of HF with careful echocardiographic phenotyping to understand the relationship of a set of microRNAs on left ventricular remodeling and their expression in models of HF development.
• We found that microRNAs identify individuals at risk for remodeling and that expression of several microRNAs was dysregulated in the heart during HF development in mice and in a cellular model of pathological hypertrophy.
WHAT ARE THE CLINICAL IMPLICATIONS?
• Biomarkers for cardiac remodeling in HF are limited to proteins that reflect downstream hemodynamic properties (eg, N-terminal pro-B-type natriuretic peptide) or extant cardiac injury (eg, cardiac troponin). Novel approaches that can identify progressive left ventricular remodeling before its occurrence (and potential biomarkers of response to therapy) may help clinicians identify the highest risk individuals for more aggressive prevention and surveillance.
• These results provide initial evidence supporting the use of microRNAs to identify individuals at risk for poorer cardiac remodeling during medical therapy.
Transthoracic Echocardiography
We performed transthoracic echocardiography at baseline and an average of 10 months after randomization using a commercially available ultrasound system (ie33; Phillips Healthcare, Andover, MA; 1.9-3.8 mHz phased-array transducer). Two-dimensional imaging (including pulse wave and color flow Doppler) was performed from standard parasternal and apical transducer positions (frame rate, 60-100 frames/s) and stored digitally. Off-line analysis of echocardiographic data was performed on a standard interpretation platform (Xcelera, Phillips Healthcare; R.W., A.B.), blinded to study time point, randomization, or clinical data. Echocardiographic measurements were performed according to society guidelines 17 and have been previously reported. 16 Briefly, LV ejection fraction and volumes were calculated using a modified Simpson biplane technique. LV reverse remodeling (LVRR) was defined as a fall in LV end-systolic volume index ≥15%, as has been defined in published trials. 18 
miRNA Quantification
We quantified 51 miRNAs from 2 sources: (1) published roles in cardiovascular disease; (2) from a screening effort in our laboratory using next-generation RNA sequencing from plasma in postmyocardial infarction patients 19 (these data are available to the general scientific committee as part of National Institutes of Health extracellular RNA Communication Consortium effort on exRNA.org). Of these 51 miRNAs, 2 had below-detection limit assays in all samples (miR-133a-5p and miR-658) and were not included in the analysis (Table I in the Data Supplement). Samples from the PROTECT trial were thawed on ice and centrifuged at 2000g to remove residual cellular debris. RNA quantification was performed using the Multiplex Circulating FirePlex miRNA Assay (Abcam, Cambridge, MA) based on gel microparticle technology. 20 Methods for miRNA quantification using the FirePlex platform are provided in the Data Supplement.
Statistical Analysis
Standard descriptive statistics were used for measures of central tendency (mean and SD, median and interquartile range), with between-group comparisons performed using parametric or nonparametric tests (as appropriate). To construct parsimonious profiles of interrelated miRNAs, we performed PCA, with retention of 4 principal components (PCs) based on a plateau in variance explained on a scree plot. FirePlex expression values for each candidate miRNA (Table I in the Data Supplement) were mean centered and standardized (to mean 0, SD 1) and entered into a PCA with varimax rotation. As noted above, below-detection threshold miRNA values were counted as 0 for inclusion into standardization and PCA. A PC score was created as the linear combination of miRNAs, weighted by their respective PCA loading.
To identify which PCs were associated with reverse LV remodeling (LVRR), we used a backward selection logistic model with LVRR as the dependent variable and the first through fourth PCs as dependent variables (retention P<0.05). Given that the second PC emerged from this analysis, we examined its ability to discriminate LVRR using logistic regression with a leave-one-out cross-validation approach (a form of internal validation) was performed to account for optimism in regression estimates. Given a limited number of LVRR events, we also explored the discriminative ability of a clinical model (age, sex, log-transformed N-terminal pro-B-type natriuretic peptide, and LV ejection fraction), using a similar approach.
In a separate analysis, we wished to confirm that further transformation of the data would not alter our results. As such, we (1) used 50% of the detection limit in place of below-detection limit values for miRNAs, (2) log-transformed these results, and (3) performed a PCA in a similar fashion as above. Of the 4 PCs identified, we tested which one(s) were associated with LVRR as above, identifying the third PC in this analysis as significantly associated with LVRR. To test the similarity between the second PC in our original analysis and the third PC in this sensitivity analysis, we plotted and calculated Pearson correlation coefficients between these 2 PCs in terms of (1) loadings for each miRNA and (2) PC scores.
Network analysis was used to identify novel gene targets not described in HF simultaneously regulated by multiple miRNAs. Proteins connected to 3 miRNAs were highlighted in green, and targeting interactions with strong experimental evidence were visualized with thicker lines. Detailed methods for network analysis bioinformatics are presented in the Data Supplement. All statistics were performed using SAS 9.3 (SAS Institute, Cary, NC) or R (R project). A 2-tailed P<0.05 was considered significant.
miRNA and mRNA Expression in a Murine Model of Hypertrophy and HF

Mouse Models
We studied 21 male C56BL/6 mice (12-week-old) subjected to either sham surgery (8 mice) or transverse aortic constriction (TAC; 13 mice) to induce pressure overload HF, as previously described. 21 A total of 8 mice (4 TAC and 4 sham) were euthanized 4 weeks after surgery, and a total of 13 mice (9 TAC mice and 4 sham) were euthanized 6 to 8 weeks after surgery for myocardial tissue harvest. Mice were monitored with transthoracic echocardiography without anesthesia at baseline, 4 weeks, and (for the group euthanized later) 6 weeks post-surgery. Progression of HF was assessed using echocardiographic and gravimetric data. We measured fractional shortening and septal thickness by M-mode echocardiography without sedation to limits the effects of anesthesia on cardiac function. At each euthanasia, heart and lung weight (normalized to tibia length) were assessed to determine the degree of cardiac dysfunction and HF, relative to 4 age-matched shams.
RNA Analysis
Total RNA was isolated from murine heart tissue using the Exiqon miRcury total RNA isolation kit following the manufacturer's protocol; total RNA was isolated from plasma using the Exiqon miRcury Biofluids kit following the manufacture's protocol. Real-time reverse transcription (RT) quantitative polymerase chain reaction (qPCR) for myocardial tissue mRNA was performed using 1 microgram input (TaqMan Multiscribe system, Thermofisher Scientific for RT; Kapa Sybr Green system for qPCR, Kapa Biosystems). For tissue miRNAs, 20 nanogram RNA input/20 microliters reaction was used in the Exiqon universal cDNA synthesis kit II for RT. For plasma miRNAs, the maximum allowable volume of extracted RNA was added to the Exiqon universal cDNA synthesis kit II for RT (7 μL per 10 μL RT reaction). For qPCR for both plasma and tissue miRNAs, Exiqon ExiLENT SYBR Green with Exiqon miR LNA PCR primer set UniRT, specific to each miRNA, were used. mRNA quantification was determined as fold change versus housekeeping gene (2 −
∆∆
Ct normalized to Hypoxanthine Guanine Phosphoribosyltransferase). miRNA quantification in plasma and tissue was determined as fold change (2 −
Ct normalized to spike-in Caenorhabditis elegans miR-39 for plasma; versus U6 small nuclear RNA snRNA for tissue). All miRNAs with murine homologs were assayed in plasma; however, only 3 (200a-3p, 193b-5p, and 15a-5p) produced detectable signals within 40 cycles of qPCR. PCRs were run in duplicate for each sample and primer, with averages used in analysis. Standard methods for analysis of fold change in quantitative PCR and pooled SE calculation were used; statistical comparisons between groups were performed as unpaired t testing of ∆ Ct values in different groups. Bonferroni adjustment of type 1 error was used where appropriate to adjust for multiple comparisons.
Cellular Models
Neonatal rat ventricular myocytes (NRVMs) were isolated and plated 2 million cells/60 mm Corning Primeria cell culture dishes. Each experiment involved 3 independent cell preparations, each run in at least duplicate. After 24 hours, cells were transfected using 2 μL lipofectamine 3000 and 300 μL Optimem (LifeTechnologies) according to the manufacturer's protocol. Cells were transfected with 50 pmol miR-423-5p mimic, or 50 pmol miR-212-5p mimic, or 50 pmol All Stars Negative Control (LifeTechnologies) in serum-free media (DMEM, 5% Pen-strip, 5% l-glutamine; LifeTechnologies). After 24 hours, the media was replaced with more serumfree media, and cells were allowed to incubate for 24 more hours before harvest. To identify cellular sources of miRNAs, we studied NRVMs, cultured primary mouse fibroblasts and endothelial cells (isolated according to prior work 22 ).
Phenylephrine Treatment
NRVMs were isolated and plated identically to those used for transfection experiments. At 24 hours after plating, cells were placed in serum-free media with 0.2 mol/L phenylephrine (Sigma-Aldrich) or PBS (vehicle). Cells were incubated for 24 hours and then harvested.
Cell Harvest, RNA Isolation, and Quantification
Cells were washed once in PBS and pelleted at 1000 rpm for 5 minutes before being resuspended in 200 μL of Cell Disruption Buffer from the miRvana Paris Total RNA Isolation Kit (LifeTechnologies). RNA isolation was performed as per the manufacturer's protocol. RT and qPCR for miRNA and mRNA quantification was performed in an identical manner as described above. We measured myocardial expression of selected miRNAs among those in the second PC with a loading >0.60 (Figure 1 ), including miR-200a-3p, miR-208a-3p, miR-212-5p, miR-423-5p, miR-193b-5p, miR-15a-5p, miR-221-5p. We next selected joint mRNA targets as those mRNAs targeted by 3 miRNAs in the network (14 mRNAs). A list of genes, miRNAs, and known function are shown in Table I in the Data Supplement. For cellular expression experiments (fibroblasts, endothelial cells, NRVMs), RNA was isolated from cells using Trizol according to the manufacturer's protocol. Quantitative RT-qPCR for miRNA expression was performed with 80 ng RNA using the miRCURY LNA Universal RT microRNA PCR kit from Exiqon per the manufacturer's protocol (with normalization to a spike-in UniSp6).
RESULTS
Baseline Characteristics
Characteristics of the 64 participants in our RNA study from the overall 151 PROTECT participants are shown in Table 1 . Study participants were predominantly older men (mean age, 64.8 years; 91% men), with near equivalent distribution of ischemic and nonischemic HF in those with known pathogenesis of cardiomyopathy. We observed a high utilization of guideline-directed HF therapies in our cohort. Baseline echocardiographic characteristics in our study cohort demonstrated moderate-to-severe LV dysfunction (median LV ejection fraction, 26%) with evidence of pulmonary hypertension (right ventricular systolic pressure 43 mm Hg) and LV dilatation ( Table 2 ). Of note, there were no statistically significant differences in clinical or echocardiographic indices between our population and study participants without sufficient plasma available for miRNA analysis.
miRNAs at Baseline Discriminate Risk of LV Remodeling With Medical Therapy and Are Related to High of Fibrosis
PCA of all candidate miRNAs demonstrated 4 PCs that accounted for 64.2% of total variation (Table II in the Data Supplement; Figure 1 ). There were no significant associations between known markers of HF-related risk (galectin-3, the interleukin-1 receptor family, suppression of tumorigenecity 2, ST-2, high-sensitivity troponin T, or N-terminal pro-B-type natriuretic peptide) and each of the 4 PCs in our study (data not shown). Of the 64 study participants, 26 individuals (41%) exhibited LVRR. In a backward selection model for LVRR including all 4 PCs as independent variables, a greater score for the second PC was associated with LVRR (odds ratio=3.99; 95% CI, 1.33-11.9; P=0.01), which yielded moderate discrimination for LVRR (cross-validated C statistic=0.712; 95% CI, 0.582-0.841; P<0.05; Figure 2 ). In a sensitivity analysis using a logistic model for LVRR that included clinical indices (age, sex, log-transformed N-terminal pro-B-type natriuretic peptide, and LV ejection fraction), the cross-validated C statistic for the clinical model was lower (0.578; 95% CI, 0.435-0.722). In our sensitivity analyses using the 50% detection limit imputation and log-transformation (see Statistical Analysis), we found concordance between miRNA loadings between the approach above (zero imputation for below-detection limit values, without log-transformation) and a sensitivity analysis involving imputation of 50% of the detection limit for below-detection limit values, followed by log-transformation (Table II and 
Network Analysis Based on Clinical Results
We first used a bioinformatics approach to identify specific genes of interest targeted by our miRNAs. We entered miRNAs in the second PC (loading >0.60: miR193b-5p, miR-15a-5p, miR-29a-5p, miR-629-5p, miR200a-3p, miR-4485-3p, miR-1278, miR-212-5p, miR208a-3p, miR-221-5p, and miR-423-5p ) into a network model to define distinct HF-related targets for further study (Figure 3 ). We observed a significant degree of overlap in gene targets of the different candidate miRNAs associated with LV remodeling in our human study, with 14 different genes noted to be targeted by 3 miRNAs (Table III in septal thickness (4 weeks TAC=1.11 mm in 8 mice; 6 weeks TAC=0.87 mm in 4 mice; P<0.05). Gravimetric data from these mice demonstrated a further increase in heart weight/tibia length (4 weeks TAC=6.9 g/m,; 6 weeks TAC=8.9 g/m; P<0.05) and lung weight/tibia length (4 weeks TAC=6.5 g/m; 6 weeks TAC=8.6; P<0.05). In parallel to development of phenotypic hypertrophy and HF, myocardial atrial natriuretic peptide and B-type natriuretic peptide expression was greater at both stages of HF development (relative to sham; Figure  II in the Data Supplement). From miRNAs in the second PC from human studies, we found that miR-423, -221, and -212 were increased in mice at the hypertrophy and HF stage relative to sham; miR-193b, -15a, and -208a were only increased at the HF stage versus sham ( Figure 4A ). When we examined myocardial expression of genes targeted by at least 3 of these miRNAs, 10 of the 13 genes were downregulated (relative to sham) in the hypertrophy or HF stage ( Figure 4B ). Finally, of the miRNAs in the second PC assayed in plasma from mice during HF development, we found an increase in miR200a, -193b, and 15a in circulation, predominantly at the HF stage ( Figure III in the Data Supplement) while the other miRNAs could not be detected by our assay in the murine plasma samples (data not shown).
Given the variety of cell types in the heart, we next hypothesized that changes seen in human LVRR in circulation would be present in cardiomyocytes exposed to stress. Alongside an increase in myocardial atrial natriuretic peptide and B-type natriuretic peptide expression after phenylephrine exposure in NRVMs ( Figure IV Finally, to further assess the cell type of origin of miRNAs studied here, we examined expression of the miRNAs in isolated NRVMs (cardiomyocytes; n=3), cultured primary fibroblasts (n=3), and endothelial cells (n=4; Figure V in the Data Supplement). Cardiomyocytes and endothelial cells (relative to fibroblasts) appeared to be an enriched source of many of the studied miRNAs.
DISCUSSION
Here, we demonstrate that multiple plasma extracellular miRNAs associated with LVRR in a well-pheno- typed human cohort of systolic HF are dysregulated in ventricular tissue from murine HF models and identify a set of mRNA targets and networks heretofore not widely investigated in HF. First, in a cohort of 64 individuals with chronic HF and reduced ejection fraction, we identified an miRNA pattern in the plasma at baseline (PC 2) that provided discrimination for LVRR to a greater degree than standard clinical risk parameters. Network and pathway analysis of these miRNAs revealed involvement in pathways relevant to myocardial hypertrophy and HF, including AMP kinase, mitogen associated protein kinase, transforming growth factor-β, and interleukin 2 signaling. Moreover, based on network analysis, we identified genes targeted by at least 3 miRNAs; the majority of these genes had not previously been described widely in HF pathogenesis. In both cellular and mouse models of hypertrophy and HF, expressions of several candidates from the human study (miR-212-5p, miR-423-5p, miR-193b-5p, and miR-221-5p) were progressively upregulated, with decreased expression of targeted mRNAs in tissue models. In addition, plasma expression of selected miRNAs was increased during HF pathogenesis. These findings support a hypothesis that multiple miRNAs identified in a phenotypic association study of human LVRR can target shared mRNAs that are dysregulated in model HF systems, identifying pathways not previously implicated in LV remodeling for further study. Further experimentations from human HF tissue are needed to validate these findings in the context of human HF but are in line with emerging evidence that miRNA networks are likely important in disease pathogenesis. 12, 13 Plasma miRNAs have emerged as relevant functional molecules involved in biological processes central to cardiovascular disease, including fibrosis, atherosclerosis, and arrhythmia. [1] [2] [3] Clinical efforts to translate miRNAs as the next natriuretic peptide for HF have been limited to association studies of a single or small subset of miRNAs with a definite outcome (eg, HF hospitalization or mortality). Unfortunately, few large studies have demonstrated significant discriminatory power of miRNAs for these multifactorial outcomes not directly connected to the underlying miRNA biology, and miRNAs identified in smaller outcome studies do not consistently validate. Hence, targeting discovery toward outcomes relevant to HF prognosis, modifiable by medical therapy, and directly related to the influence of miRNAs on the underlying biology is warranted. In this study, we address this approach by leveraging detailed echocardiographic phenotypes of LVRR-a prognostic measure in HF-in patients with systolic HF.
Several miRNAs associated with LVRR in humans had been previously implicated in target gene regulation in hypertrophy, fibrosis, and inflammatory pathways germane to LVRR (eg, miR-208a 23, 24 and miR-29a 25 ), and we observed that selected molecular pathways with established import in LV remodeling were regulated by several miRNAs identified in our human study. We further used a network-based analytic approach to examine whether genes targeted by multiple miRNAs in our network would be regulated alongside miRNAs. Several of the miRNAs identified in our human cohort had been previously investigated in mouse models (eg, miR-212 26, 27 , miR-423-5p, 28 and miR-221 29 ). In addition, our translational approach identified thioredoxininteracting protein as a target of both miR-423 and miR-212 (increased in animal models of hypertrophy/ HF). Thioredoxin-interacting protein has been implicated in regulation of myocardial hypertrophy after pressure overload 30 and myocardial metabolism, with a biphasic response (early protective, late deleterious) to TAC in thioredoxin-interacting protein −/− mice. 31 Nevertheless, several other targets (eg, AAK1, RBM28) are regulated by miRNAs altered in human and animal HF and to our knowledge have not been implicated extensively in HF pathogenesis. Although we recognize that ascribing myocardial relevance to many of the novel targets uncovered in this study is speculative (Table II in the Data Supplement) and requires direct confirmation, our finding that key, nodal genes that are regulated by ≥3 candidate miRNAs are downregulated during HF progression supports a translational approach that leverages human and animal data for pathway discovery in HF.
One additional strength of the study is the use of the FirePlex system for miRNA quantification. Current translational studies of miRNA biology in humans use RNA sequencing or PCR-based methods for quantification, which multiple prequantitation steps (eg, RNA isolation, library construction) that may introduce bias or loss of input RNA from an already low circulating quantity. The FirePlex assay has unique, clinically translatable benefits in this regard given the ability to use a small input quantity without a priori RNA isolation.
The strength of our study is its prospective design, guideline-directed HF management, and detailed echocardiographic and miRNA quantification. We recognize that our clinical study sample is small, with limited power for full adjustment of clinical and RNAbased biomarkers. Furthermore, lack of an external cohort for validation across multiple time points limits the generalizability of this result. Future studies that catalog detailed echocardiographic phenotypes longitudinally, with more complete characterization of cardiomyopathy pathogenesis and a more extensive array of biomarkers under optimal medical therapies, will provide this opportunity (PROVE-HF [Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes]; NCT02887183). Although it would have been desirable to have echocardiography performed at exact time intervals for each patient, because of study design, the average timing of echocardiography was 10±2 months after study enrollment. 32 Although this may impact associations between miRNAs and LVRR, this data set has been studied with consistently robust results relative to LVRR with other biomarkers. [33] [34] [35] [36] With regard to animal investigation, we did not perform detailed genetic or pharmacological gain-and loss-of-function for the noncoding RNAs associated with LVRR. However, more detailed mechanistic studies have been performed for several of these candidate RNAs in the past. [26] [27] [28] [29] Among many others, further investigations in this regard prompted by these results should focus on 2 major areas: (1) understanding whether myocardial and plasma alterations that occur in model systems are directionally consistent with effects in humans; (2) whether alterations of these miRNAs in the plasma and heart in model systems or in plasma with humans (eg, with therapies) can uniquely identify a cohort of patients with LVRR and are predictive of long-term outcomes.
In conclusion, we demonstrate the use of leveraging multiple circulating miRNAs dysregulated during LVRR in humans both as a step in clinical biomarker development as well as uncovering novel genes targeted by multiple miRNAs in novel pathway discovery. Further work in large cohorts of LV recovery (eg, mechanical unloading) or chronic HF therapy can use not only the specific RNAs and targets uncovered in this study but also the general approach for multimarker miRNA discovery at the intersection of human and animal biology in HF. 
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